safety analysis by treatment periods from Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Chan, S.; Sangro, B.; Kudo, M.; Erinjeri, J.; Qin, S. K.; Ren, Z. G.; Arai, Y.; Breder, V.; Lin, S. M.; Peron, J. M.; Nguyen, Q.; Yan, L. N.; Chiu, C. F.; Santos, F.; Veluvolu, A.; Thungappa, S. C.; Morgan, C.; Parsons, K.; Xynos, I.; Lencioni, R. |
| Abstract Title: | safety analysis by treatment periods from Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma |
| Meeting Title: | Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2024): The Liver Meeting |
| Journal Title: | Hepatology |
| Volume: | 80 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Nov 15-19 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2024-10-01 |
| Start Page: | S1444 |
| End Page: | S1445 |
| Language: | English |
| ACCESSION: | WOS:001366004003437 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1900 -- Source: Wos |
MSK Authors
-
200Erinjeri